Justin Di Lu

Justin Di Lu

Auto-generated profile, based on publicly available information

Justin Di Lu

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
JLJustin D. Lu
Justin D. Lu
STSabeen Tiwana
Sabeen Tiwana
PDPriya Das
Priya Das
JSJaved Siddiqi
Javed Siddiqi
FKFaisal Khosa
Faisal Khosa

29 September 2020 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
JLJustin D. Lu
Justin D. Lu
MMMilica Milakovic
Milica Milakovic
ALAlex Ortega Loayza
Alex Ortega Loayza
Angelo MarzanoAngelo Marzano
Angelo Marzano
AAAfsaneh Alavi
Afsaneh Alavi
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis with no FDA approved treatment. The complement pathway has received renewed attention because it is elevated in inflammatory cutaneous co...

19 November 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
JLJustin D. Lu
Justin D. Lu
AMAsfandyar Mufti
Asfandyar Mufti
MSMuskaan Sachdeva
Muskaan Sachdeva
SRShahmina Rahat
Shahmina Rahat
RLRafael Paolo Lansang
Rafael Paolo Lansang
JYJensen Yeung
Jensen Yeung

30 March 2022 in JMIR Dermatology
Verified
Journal Article
Open access
JLJustin Di Lu
Justin Di Lu
RGRyan D Gotesman
Ryan D Gotesman
SVShawn Varghese
Shawn Varghese
PFPatrick Fleming
Patrick Fleming
CLCharles Lynde
Charles Lynde
Background: Delusional infestation, also known as Ekbom syndrome, is a rare delusional disorder characterized by the fixed belief that one is infested with parasites, worms, insects, or other organisms. Although delusional infestation is a psychiatric condition, patients often consult dermatologists with skin findings, and it is currently unclear what treatments are recommended for this disorder.Objective: We aimed to systematically review and describe the treatment and management of patients presenting with primary delusional infestation.Methods: A systematic search was conducted using Ovid on MEDLINE, Embase, PsycINFO, and the Cochrane Register of Clinical Trials. Relevant data, including treatment, dosage, response, adherence, and side effects, were extracted and analyzed.Results: A total of 15 case series were included, comprising 280 patients (mean age 53.3 years, 65.4% female) with delusional infestation. Overall, aripiprazole had the highest complete remission rate at 79% (11/14), although this was limited to 14 patients. Among drug classes, selective serotonin reuptake inhibitors were the most effective with a 79% (11/14) complete remission rate and 43% (9/21) partial remission rate in patients with comorbid depression, anxiety, or trichotillomania. First-generation antipsychotics and second-generation antipsychotics had similar complete remission rates (56/103, 54.4% vs 56/117, 47.9%, respectively) and partial remission rates (36/103, 35% vs 41/117, 35%, respectively).Conclusions: Due to the rarity of delusional infestation, we only found 15 case series. However, we found that first-generation antipsychotics appear to be similar in effectiveness to second-generation antipsychotics for the treatment of primary delusional infestation. Larger studies and randomized controlled trials are needed to evaluate the efficacy of pharmacological therapy for delusional infestation.Trial Registration: PROSPERO CRD42020198161; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=198161

6 May 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JLJustin D. Lu
Justin D. Lu
MSMuskaan Sachdeva
Muskaan Sachdeva
OSOrli M. Silverberg
Orli M. Silverberg
LSLee Shapiro
Lee Shapiro
DCDavid Croitoru
David Croitoru
RLRebecca Levy
Rebecca Levy
Background: Degos disease is a rare vascular disorder with a cutaneous-limited form, benign atrophic papulosis (BAP), and a systemic variant, malignant atrophic papulosis (MAP). Despite the poor prognosis of MAP, no study has established features associated with systemic disease. Objectives: The aims of this systematic review were to: (1) summarize clinical features and treatments implemented for patients with MAP and BAP (2) identify clinical and laboratory factors associated with the development of MAP, compared to BAP. Methods: We systematically searched MEDLINE and Embase from inception to April 2020. Demographic and clinical features of Degos patients were presented descriptively; multivariable logistic regression was performed to identify associations with MAP. Results: We identified 99 case studies, comprising 105 patients. MAP (64%) had a 2.15 year median survival time from cutaneous onset, most often with gastrointestinal or central nervous system involvement. We found that elevations in either of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) were associated with systemic involvement (OR 2.27, p = 0.023). Degos secondary to an autoimmune connective tissue disease was found to be inversely associated with MAP (OR 0.08, p = 0.048). Conclusions: Elevated ESR or CRP is associated with MAP and may be a predictor of systemic involvement for patients with Degos disease. In addition, secondary Degos disease is associated with a favourable prognosis. Clinicians should be aware of the differences between primary and secondary Degos and the utility of ESR or CRP in identifying disease evolution to systemic involvement. The utility of ESR and CRP to identify systemic involvement should be further explored.

31 August 2020 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
MLMegan Lam
Megan Lam
JSJeremy Steen
Jeremy Steen
JLJustin Di Lu
Justin Di Lu
RVRonald Vender
Ronald Vender
Background: The systemic effects and comorbidities of psoriasis include ocular disorders, such as uveitis. Patients with psoriatic arthritis in particular have been demonstrated to have an elevated risk for developing uveitis. Presently, the risk of uveitis in psoriasis has yet to be fully elucidated and this systematic review seeks to address this gap. Objective: To examine the prevalence and incidence of uveitis in psoriasis patients compared to non-psoriasis patients. Methods: We conducted a systematic review search on MEDLINE, Embase, and CENTRAL electronic databases with no lower limit on year of publication. Results: Fourteen articles met our inclusion criteria, with a total of 234 143 psoriasis subjects. Two studies found that participants with severe psoriasis were at a greater risk of uveitis than those with mild psoriasis. A random-effects meta-analysis of the 3 studies, which reported risk of incidence of uveitis in psoriasis patients compared to non-psoriasis controls, found a pooled risk ratio of 1.29 (95% CI, 1.10-1.51), indicating an increased risk of uveitis in psoriasis. Three studies compared risk of uveitis in psoriatic arthritis with psoriasis-only participants, all finding that psoriatic arthritis was associated with a greater risk of uveitis. Conclusions: In summary, our findings suggest that psoriasis is associated with an increased risk of uveitis, with or without psoriatic arthritis.